Genomic medicine company Chroma Medicine Inc announced on Thursday the appointment of Melissa J Moore, PhD to its board of directors.
Dr Moore is currently a board director and Scientific Advisory Board member for multiple biotechnology companies. She previously served as chief scientific officer, Platform Research, at Moderna Inc (NASDAQ:MRNA).
Dr Moore co-founded the RNA Therapeutics Institute at the University of Massachusetts Medical School and was a professor of Biochemistry & Molecular Pharmacology, Eleanor Eustis Farrington Chair in Cancer Research, and a long-time Investigator at the Howard Hughes Medical Institute.
Catherine Stehman-Breen, M.D., Chroma CEO, said: "Melissa brings decades of experience directing RNA research and drug development at leading pharma companies and in academia. Her deep knowledge will benefit us as we advance our platform of highly potent and durable epigenetic editors to patients, enabling a new class of genomic medicines."
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer
iOncologi acquires TargImmune Therapeutics
Akeso's Penpulimab receives Chinese regulatory approval
Argent BioPharma announces positive CimetrA Phase IIb clinical trial results
ANI Pharmaceuticals secures FDA approval for ILUVIEN label expansion
Korro Bio receives FDA orphan drug designation for KRRO-110
BRAVO study confirms blue light cystoscopy reduces bladder cancer recurrence risk
Merck reports positive Phase 3 Data on HIV treatment DOR/ISL
Cantargia enrolls first patient in leukemia study with nadunolimab
Shilpa Medicare's Nor Ursodeoxycholic Acid Tablets IND receives regulatory approval in India
Centivax partners with Emery Pharma on universal flu vaccine
OsteoCentric Technologies partners with Globus Medical to expand innovative implant technology
Arvinas and Pfizer report positive Phase 3 results for vepdegestrant in breast cancer trial
PHI advances Next-Generation HoloMonitor CellSync for cell and gene therapy